Client
NorChip AS, Klokkarstua, Norway
Developing and marketing PreTect® HPV-Proofer, a cost-effective diagnostic assay for the detection of cervical cancer in women of all ages, identifying the expression of E6/E7 mRNA coding for HPV proteins E6/E7 from HPV types 16, 18, 31, 33 and 45.
Mandate
Board Advisory Services
Our Role
Retained advisor to the Board of Directors and management
- Attended Board meetings in person or via conference call.
- Consulted on strategy and competitive position of the PreTect® HPV-Proofer assay.
- Consulted management on investor outreach and ongoing fundraising efforts.
- Accompanied management to meetings with prospective strategic partners and collaborators.
N.B. Consulting services performed prior to the formation of CATALYSIS CAPITAL PARTNERS LTD. and authorisation and regulation by FCA UK
